Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives

Abstract

Aims: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. While patients who are known to be at high risk for HCC should be under surveillance, only 20% of eligible patients in the United States are surveilled. The aim of this study was to identify providers’ perspectives about patient-, provider- and system-level barriers to surveillance for HCC among high-risk patients and to examine provider knowledge and attitudes related to HCC surveillance. We also explored interventions providers suggested as ways to improve HCC surveillance.

Methods: Purposive sampling was used to recruit physicians and nurse practitioners in hepatology, gastroenterology, and primary care (internal and family medicine) from one academic medical center to participate in semi-structured interviews. Interviews were transcribed verbatim, and analyzed deductively and inductively to reveal emergent themes.

Results: 22 informants were interviewed. During these interviews, several important themes emerged, including: (1) Provider comfort with managing chronic liver disease and the relationships between hepatology, gastroenterology, infectious disease, and primary care providers; (2) Provider knowledge of guidelines for HCC surveillance in high-risk patients and their knowledge about the impact that HCC surveillance can have; (3) How providers discuss HCC surveillance with their high-risk patients; (4) Provider-Level barriers to surveillance; (5) System-level barriers to surveillance; (6) COVID-19; (7) Patient-level barriers to surveillance, and (8) Suggested interventions to improve HCC surveillance rates.

Conclusions: In designing interventions to improve HCC surveillance rates of high-risk patients in the United States, there are important targets at the patient, provider and system levels.

Keywords

Hepatocellular carcinoma (HCC) / cancer screening / cirrhosis / chronic liver disease

References

[1] Akinyemiju T,Ahmed M.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol2017;3:1683-91

[2] Kanwal F.Surveillance for hepatocellular carcinoma: current best practice and future direction.Gastroenterology2019;157:54-64 PMCID:PMC6636644

[3] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[4] Yang B,Xu Y.Prospective study of early detection for primary liver cancer.J Cancer Res Clin Oncol1997;123:357-60

[5] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004;130:417-22

[6] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[7] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70.

[8] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[9] Covey AM.Hepatocellular carcinoma: updates to screening and diagnosis.J Natl Compr Canc Netw2018;16:663-5

[10] Singal AG,S Skinner C,Lee WM.Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.J Gen Intern Med2012;27:861-7 PMCID:PMC3378733

[11] Sloane D,Howell C.Racial disparity in primary hepatocellular carcinoma : tumor stage at presentation, surgical treatment and survival.J Natl Med Assoc2006;98:1934-9. PMCID:PMC2569668

[12] Ha J,Aguilar M.Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.Cancer2016;122:2512-23

[13] Singal AG,Gupta S.Failure rates in the hepatocellular carcinoma surveillance process.Cancer Prev Res2012;5:1124-30 PMCID:PMC3435471

[14] El-Serag HB,Richardson P.Hepatocellular carcinoma screening practices in the department of veterans affairs: findings from a national facility survey.Dig Dis Sci2013;58:3117-26 PMCID:PMC3858077

[15] Shavers VL.Racial and ethnic disparities in the receipt of cancer treatment.J Natl Cancer Inst2002;94:334-57

[16] Parikh ND,Al-Jarrah T.Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort.JAMA Netw Open2022;5:e2223504 PMCID:PMC9308050

[17] Beal EW,McNamara M,Tsung A.Patient-, provider-, and system-level barriers to surveillance for hepatocellular carcinoma in high-risk patients in the USA: a scoping review.J Gastrointest Cancer2023;54:332-56

[18] Simmons OL,Parikh ND.Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance.Clin Gastroenterol Hepatol2019;17:766-73 PMCID:PMC7212522

[19] Dalton-Fitzgerald E,Kandunoori P,Yopp A.Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2015;13:791-8.e1 PMCID:PMC4289665

[20] Glaser BG. More grounded theory methodology: a reader. Available from: https://www.amazon.com/More-Grounded-Theory-Methodology-reader/dp/188415607X[Last accessed on 25 Oct 2023].

[21] Crabtree B. Doing qualitative research. Available from: https://www.amazon.com/CRABTREE-QUALITATIVE-RESEARCH-Research-Paperback/dp/0761914986 [Last accessed on 25 Oct 2023]

[22] Constas MA.Qualitative analysis as a public event: the documentation of category development procedures.Am Educ Res J1992;29:253-66.

[23] ATLAS.ti (Software). Available from: https://atlasti.com/ [Last accessed on 25 Oct 2023]

[24] Beste LA,Yang Y,Ross D.Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder.Clin Gastroenterol Hepatol2015;13:172-9

[25] Russo MW,Koteish AA.Modeling the hepatology workforce in the United States: a predicted critical shortage.Hepatology2020;72:1444-54

[26] Russo MW,Fuchs M,Fix OK.Workforce in hepatology: update and a critical need for more information.Hepatology2017;65:336-40

[27] Ladhani S,Wong RJ.Disparities in hepatocellular carcinoma surveillance: dissecting the roles of patient, provider, and health system factors.J Clin Gastroenterol2020;54:218-26

[28] Toyoda H,Le MH.Liver care and surveillance: the global impact of the COVID-19 pandemic.Hepatol Commun2020;4:1751-7 PMCID:PMC7405084

[29] Mancebo G,Membrive I.Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19).Int J Gynecol Cancer2021;31:914-9

[30] D'Ovidio V,Bruno G,Miglioresi L.Impact of COVID-19 pandemic on colorectal cancer screening program.Clin Colorectal Cancer2021;20:e5-11 PMCID:PMC7391078

[31] Vose JM.Delay in cancer screening and diagnosis during the COVID-19 pandemic: what is the cost?.Oncology2020;34:343

[32] London JW,Palchuk MB,McNair C.Effects of the COVID-19 pandemic on cancer-related patient encounters.JCO Clin Cancer Inform2020;4:657-65 PMCID:PMC7444638

[33] Zeng G,Kennedy PTF.Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis.Gut2020;69:1907-12 PMCID:PMC7295856

[34] Paredes AZ,Beal EW.Impact of skilled nursing facility quality on postoperative outcomes after pancreatic surgery.Surgery2019;166:1-7

[35] Mehta N,Kelley RK,Singal AG.Surveillance and monitoring of hepatocellular carcinoma during the COVID-19 pandemic.Clin Gastroenterol Hepatol2021;19:1520-30 PMCID:PMC7342037

[36] Seo YS,Um SH.Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study.Oncotarget2017;8:113213-24 PMCID:PMC5762585

[37] Goldberg DS,Serper M.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.Hepatology2017;65:864-74

[38] Farvardin S,Khambaty M.Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.Hepatology2017;65:875-84 PMCID:PMC5568252

[39] Singal AG,Tiro J.Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.Am J Med2015;128:90.e1-7 PMCID:PMC4282818

[40] Guo A,Wattacheril J.Health disparities in screening, diagnosis, and treatment of hepatocellular carcinoma.Clin Liver Dis2021;17:353-8 PMCID:PMC8177833

[41] Fitzmorris P.Surveillance and diagnosis of hepatocellular carcinoma.Gastro Hepat2015;11:38-46. PMCID:PMC4836577

[42] Aberra FB,Fisher N.Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis.Dig Dis Sci2013;58:1157-60

[43] Singal AG,Marrero JA.Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma.Gastroenterology2017;152:608-15.e4 PMCID:PMC5285373

[44] Singal AG,Murphy CC.Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial.Hepatology2019;69:121-30. PMCID:PMC6324997

[45] Yoder L,Pike F.Attendance at a transitional liver clinic may be associated with reduced readmissions for patients with liver disease.Am J Med2022;135:235-43.e2 PMCID:PMC8840978

[46] Kennedy NA,Altus R,Wundke R.Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study.Intern Med J2013;43:772-7

[47] Shaw J,Reuter B.Focused education increases hepatocellular cancer screening in patients with cirrhosis regardless of functional health literacy.Dig Dis Sci2021;66:2603-9 PMCID:PMC7933309

[48] Artinyan A,Sanchez-Luege N.Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.Cancer2010;116:1367-77

[49] Nam JY,Kim HY.Oral medications enhance adherence to surveillance for hepatocellular carcinoma and survival in chronic hepatitis B patients.PLoS One2017;12:e0166188 PMCID:PMC5242546

[50] Cabrie T,Jacqui R. The challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer? Available from: https://www.racgp.org.au/afp/2017/november/the-challenge-of-liver-cancer-surveillance/ [Last accessed on 27 Oct 2023]

[51] Cahill JA,Saeian K.Assessment of adherence to baseline quality measures for cirrhosis and the impact of performance feedback in a regional VA medical center.Am J Med Qual2018;33:262-8

[52] Rogal SS,Gonzalez R.The hepatic innovation team collaborative: a successful population-based approach to hepatocellular carcinoma surveillance.Cancers2021;13:2251 PMCID:PMC8125814

[53] O'Leary DA,Isaac D."B in IT" - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool.Hepatol Med Policy2018;3:1